keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma with portal vein thrombosis

keyword
https://www.readbyqxmd.com/read/29439255/co-upregulation-of-14-3-3%C3%AE-and-p-akt-is-associated-with-oncogenesis-and-recurrence-of-hepatocellular-carcinoma
#1
Yufu Tang, Ruoyu Wang, Yibing Zhang, Shenhui Lin, Na Qiao, Zhongyi Sun, Shuqun Cheng, Wenping Zhou
BACKGROUND/AIMS: 14-3-3ζ is involved in the regulation of PI3K/Akt pathway which is closely associated with carcinogenesis. However, the clinical significance of combined detection of 14-3-3ζ and p-Akt in hepatocellular carcinoma (HCC) remains unclear. METHODS: Two-hundred pairs of HCC and adjacent liver specimens were subjected to tissue microarray. The association of 14-3-3ζ and p-Akt levels with the postoperative survival and recurrence in HCC patients was analyzed with univariate and multivariate methods...
February 7, 2018: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29436101/chemoembolization-related-to-good-survival-for-selected-patients-with-hepatocellular-carcinoma-invading-segmental-portal-vein
#2
Jin Hyoung Kim, Ju Hyun Shim, Hyun-Ki Yoon, Heung-Kyu Ko, Jong Woo Kim, Dong Il Gwon
BACKGROUND AND AIMS: We evaluated survival outcomes and prognostic factors associated with survival after transarterial chemoembolization (TACE) in a large cohort of 331 patients with hepatocellular carcinoma (HCC) with segmental portal vein tumor thrombosis (PVTT). METHODS: From 1997 to 2015, a total of 331 patients were included in this study from among 507 patients who underwent TACE as a first-line treatment for HCC with segmental PVTT. RESULTS: After TACE, the median survival of the whole cohort was 10...
February 13, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29428943/comparison-of-outcome-of-hepatic-arterial-infusion-chemotherapy-combined-with-radiotherapy-and-sorafenib-for-advanced-hepatocellular-carcinoma-patients-with-major-portal-vein-tumor-thrombosis
#3
Kenichiro Kodama, Tomokazu Kawaoka, Hiroshi Aikata, Shinsuke Uchikawa, Yuno Nishida, Yuki Inagaki, Masahiro Hatooka, Kei Morio, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Keiichi Masaki, Yoji Honda, Nami Mori, Shintaro Takaki, Keiji Tsuji, Hirotaka Kohno, Hiroshi Kohno, Takashi Moriya, Michihiro Nonaka, Hideyuki Hyogo, Yasuyuki Aisaka, Tomoki Kimura, Yasushi Nagata, Kazuaki Chayama
OBJECTIVE: To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT). METHODS: This retrospective study included 108 HCC patients with PVTT of the main trunk or first branch and Child-Pugh ≤7. Sixty-eight received HAIC + RT and 40 received sorafenib. Patients were then assigned to the HAIC + RT group (n = 36) and the sorafenib group (n = 36) through case-control matching...
February 9, 2018: Oncology
https://www.readbyqxmd.com/read/29420366/endoscopic-ultrasound-guided-fine-needle-aspiration-of-portal-vein-thrombosis-in-patients-with-chronic-liver-disease-and-suspicion-of-hepatocellular-carcinoma
#4
Antonio Z Gimeno Garcia, Jose R Aparicio, Angel Barturen, Miguel Moreno, David Nicolas-Perez, Enrique Quintero
BACKGROUND: Differentiation between benign and malignant portal vein thrombosis (PVT) in the setting of a hepatocellular carcinoma (HCC) is of paramount importance. Histological analysis is usually not carried out because of potential severe side effects of the percutaneous approach. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) may be safer and may guide the clinical management of patients with HCC. OBJECTIVE: To describe the feasibility of the EUS-FNA in a series of patients with HCC and PVT...
February 7, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29407630/low-molecular-weight-heparin-treatment-for-portal-vein-thrombosis-in-liver-cirrhosis-efficacy-and-the-risk-of-hemorrhagic-complications
#5
Jihyun Kwon, Youngil Koh, Su Jong Yu, Jung-Hwan Yoon
INTRODUCTION: Portal vein thrombosis (PVT) is a well-known complication in patients with liver cirrhosis (LC). The aim of this study is to investigate the outcomes of cirrhotic patients with PVT treated with low-molecular-weight heparin (LMWH). METHOD: Ninety-one LC patients with PVT were treated with dalteparin or enoxaparin for six months. Patients with major bleeding during the last three months, severe thrombocytopenia, or impaired renal function were excluded...
February 1, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29394731/-a-case-of-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-treated-successfully-with-multidisciplinary-therapy-including-preoperative-stereotactic-body-radiotherapy-sbrt
#6
Sadaaki Nishimura, Akira Tomokuni, Shogo Kobayashi, Kei Asukai, Hirofumi Akita, Hidenori Takahashi, Yoshitomo Yanagimoto, Yusuke Takahashi, Norikatsu Miyoshi, Keijiro Sugimura, Kazuyoshi Yamamoto, Takeshi Ohmori, Masayuki Ohue, Masahiko Yano, Masato Sakon
A 61-year-old man untreated with hepatitis C virus presented to our hospital.He was diagnosed advanced hepatocellular carcinoma(HCC)with portal vein tumor thrombosis(PVTT).The hazy tumor was located in the left lobe, and the tumor thrombus extended into the left portal vein.The patient received stereotactic body radiotherapy(SBRT, 48 Gy/4 Fr)for PVTT. The extended left lobectomy with thrombectomy was performed 12 days after SBRT.Resected specimen was diagnosed histopathologically as a poorly differentiated HCC, vp1, and no viable tumor cells in the tumor thrombosis...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29390197/advanced-recurrent-hepatocellular-carcinoma-treatment-with-sorafenib-alone-or-in-combination-with-transarterial-chemoembolization-and-radiofrequency-ablation
#7
Zhenwei Peng, Shuling Chen, Mengchao Wei, Manxia Lin, Chunlin Jiang, Jie Mei, Bin Li, Yu Wang, Jiaping Li, Xiaoyan Xie, Minshan Chen, Guojun Qian, Ming Kuang
Purpose To retrospectively investigate the safety and efficacy of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, TACE-RFA) in the treatment of recurrent hepatocellular carcinoma (rHCC) with portal vein tumor thrombosis, extrahepatic metastases (advanced hepatocellular carcinoma), or both after initial hepatectomy. Materials and Methods The study was centrally approved by the ethics committee of three tertiary medical centers in China. From January 2010 to January 2015, 207 consecutive patients with advanced rHCC after initial hepatectomy received sorafenib combined with TACE-RFA (combination group, n = 106) or sorafenib alone (sorafenib group, n = 101) at the three medical centers...
February 1, 2018: Radiology
https://www.readbyqxmd.com/read/29379006/long-term-outcomes-of-ante-situm-resection-and-auto-transplantation-in-conventionally-unresectable-hepatocellular-carcinoma-a-single-center-experience
#8
Qifa Ye, Cheng Zeng, Yanfeng Wang, Yingzi Ming, Qiquan Wan, Shaojun Ye, Yan Xiong, Ling Li
BACKGROUND Ante-situm resection and auto-transplantation (ante-situm for short) provides a more aggressive approach to conventionally unresectable hepatocellular carcinoma (HCC). We described the long-term outcomes of patients with HCCs who underwent this technique. MATERIAL AND METHODS Between October 2005 and December 2016, we performed 23 ante-situm liver resections. We evaluated postoperative complications, 90-day mortality, recurrence, and long-term survival rates, and reviewed the literature on this topic...
January 30, 2018: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/29373208/predictors-of-shunt-dysfunction-and-overall-survival-in-patients-with-variceal-bleeding-treated-with-transjugular-portosystemic-shunt-creation-using-the-fluency-stent-graft
#9
Yue-Meng Wan, Yu-Hua Li, Ying Xu, Hua-Mei Wu, Ying-Chun Li, Xi-Nan Wu, Jin-Hui Yang
RATIONALE AND OBJECTIVES: Transjugular intrahepatic portosystemic shunt (TIPS) is an established method for portal hypertension. This study was to investigate the long-term safety, technical success, and patency of TIPS, and to determine the risk factors and clinical impacts of shunt dysfunction. MATERIALS AND METHODS: A total of 154 consecutive patients undergoing embolotherapy of gastric coronary vein and/or short gastric vein and TIPS creation were prospectively studied...
January 16, 2018: Academic Radiology
https://www.readbyqxmd.com/read/29366520/clinical-significance-of-soluble-programmed-cell-death-ligand-1-spd-l1-in-hepatocellular-carcinoma-patients-treated-with-radiotherapy
#10
Hyun Ju Kim, Sangjoon Park, Kyoung-Jin Kim, Jinsil Seong
PURPOSE: To investigate the clinical implications of the soluble programmed cell death-ligand 1 (sPD-L1) level in hepatocellular carcinoma (HCC) patients treated with radiotherapy (RT). MATERIALS/METHODS: HCC patients treated with RT between June 2011 and March 2015 were prospectively recruited and sPD-L1 levels were measured using an enzyme-linked immunosorbent assay. Blood samples were obtained at the RT start, RT end, and 1-month follow-up. The associations of the sPD-L1 level with the clinical features and outcomes were analyzed...
January 20, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29340282/should-vasoconstrictors-be-considered-in-a-cirrhotic-patient-with-acute-non-variceal-upper-gastrointestinal-bleeding
#11
Xingshun Qi, Hongyu Li, Xiaodong Shao, Zhendong Liang, Xia Zhang, Ji Feng, Hao Lin, Xiaozhong Guo
Varices manifest as a major etiology of upper gastrointestinal bleeding in patients with chronic liver diseases, such as liver cirrhosis and hepatocellular carcinoma. By contrast, non-variceal upper gastrointestinal bleeding is rare. Pharmacological treatment differs between patients with variceal and non-variceal bleeding. Vasoconstrictors are recommended for the treatment of variceal bleeding, rather than non-variceal bleeding. In contrast, pump proton inhibitors are recommended for the treatment of non-variceal bleeding, rather than variceal bleeding...
December 2017: Journal of Translational Internal Medicine
https://www.readbyqxmd.com/read/29334777/endovascular-implantation-of-125i-seed-combined-with-transcatheter-arterial-chemoembolization-for-unresectable-hepatocellular-carcinoma
#12
Houbin Sun, Minghui Zhang, Ruibao Liu, Yan Liu, Yingwen Hou, Changjun Wu
AIM: The purpose of this study was to evaluate the efficacy and safety of the endovascular implantation of 125I seed under ultrasound and x-ray guidance combined with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). PATIENTS & METHODS: The study included 134 pathologically proven or clinically confirmed primary HCC patients with PVTT in our hospital from January 2013 to June 2015...
January 16, 2018: Future Oncology
https://www.readbyqxmd.com/read/29331342/development-of-a-prognostic-score-to-predict-response-to-yttrium-90-radioembolization-for-hepatocellular-carcinoma-with-portal-vein-invasion
#13
Carlo Spreafico, Carlo Sposito, Marta Vaiani, Tommaso Cascella, Sherrie Bhoori, Carlo Morosi, Rodolfo Lanocita, Raffaele Romito, Carlo Chiesa, Marco Maccauro, Alfonso Marchianò, Vincenzo Mazzaferro
BACKGROUND & AIMS: Yttrium-90 transarterial radioembolization (TARE) has shown promising efficacy in the treatment of patients with hepatocellular carcinoma (HCC), associated with portal vein tumor thrombus (PVTT). The aim of this study is to identify prognostic factors for survival in patients with HCC and PVTT undergoing TARE, and build a prognostic classification for these patients. METHODS: This is a single center retrospective study conducted over six years (2010-2015), on consecutive patients undergoing TARE...
January 10, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29329568/prospective-longitudinal-quality-of-life-and-survival-outcomes-in-patients-with-advanced-infiltrative-hepatocellular-carcinoma-and-portal-vein-thrombosis-treated-with-yttrium-90-radioembolization
#14
Minzhi Xing, Nima Kokabi, Juan C Camacho, Hyun S Kim
BACKGROUND: To determine the effect of Yttrium-90 (Y90) radioembolization on health-related quality of life (HRQOL) and its effect on overall survival advanced, unresectable infiltrative hepatocellular carcinoma (HCC) patients with concurrent portal vein thrombosis (PVT). METHODS: Consecutive patients with unresectable infiltrative HCC and PVT were recruited. The Short-Form 36 (SF-36) questionnaire was used to assess HRQOL for consecutive patients treated with glass-based Y90 based on a prospective phase II trial...
January 12, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29327075/phase-ii-study-of-sorafenib-combined-with-concurrent-hepatic-arterial-infusion-of-oxaliplatin-5-fluorouracil-and-leucovorin-for-unresectable-hepatocellular-carcinoma-with-major-portal-vein-thrombosis
#15
Min-Ke He, Ru-Hai Zou, Qi-Jiong Li, Zhong-Guo Zhou, Jing-Xian Shen, Yong-Fa Zhang, Zi-Shan Yu, Li Xu, Ming Shi
BACKGROUND: Sorafenib is recommended for the first-line treatment of advanced hepatocellular carcinoma (HCC). However, the median progression-free survival (PFS) of patients with HCC and major portal vein tumor thrombosis treated with sorafenib monotherapy is no more than 3 months. A prospective single-arm phase II study was conducted to determine whether adding hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin to sorafenib could improve on these results...
January 11, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29306522/visceral-thromboses-in-pancreas-adenocarcinoma-systematic-review
#16
REVIEW
Angel Mier Hicks, Antonio DeRosa, Michael Raj, Richard Do, Kenneth H Yu, Maeve A Lowery, Anna Varghese, Eileen M O'Reilly
Within gastrointestinal malignancies, primary hepatocellular carcinoma and pancreatic ductal adenocarcinoma (PDAC) are frequently associated with visceral thromboses (VT). Thrombus formation in the portal (PVT), mesenteric (MVT), or splenic vein (SVT) system leads to portal hypertension and intestinal ischemia. VT in PDAC may convey a risk of increased distal thrombosis and poses therapeutic uncertainty regarding the role of anticoagulation. An increasing number of reports describe VT associated with PDAC. It is possible that early diagnosis of these events may help reduce morbidity and speculatively improve oncologic outcomes...
December 12, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29258719/the-role-of-liver-resection-in-the-management-of-intermediate-and-advanced-stage-hepatocellular-carcinoma-a-systematic-review
#17
REVIEW
G K Glantzounis, A Paliouras, M-C Stylianidi, H Milionis, P Tzimas, D Roukos, G Pentheroudakis, E Felekouras
BACKGROUND: The ideal management for patients with intermediate and advanced stage hepatocellular carcinoma (HCC) is controversial. The main purpose of this systematic review is to examine the role of liver resection in patients with intermediate stage HCC (multinodular HCCs) and in advanced stage HCC [mainly patients with portal vein tumor thrombosis (PVTT)]. METHODS: A systematic search of the literature was performed in Pud Med and the Cochrane Library from 01...
December 12, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29249005/metronomic-capecitabine-as-second-line-treatment-for-hepatocellular-carcinoma-after-sorafenib-discontinuation
#18
Franco Trevisani, Giovanni Brandi, Francesca Garuti, Maria Aurelia Barbera, Raffaella Tortora, Andrea Casadei Gardini, Alessandro Granito, Francesco Tovoli, Stefania De Lorenzo, Andrea Lorenzo Inghilesi, Francesco Giuseppe Foschi, Mauro Bernardi, Fabio Marra, Rodolfo Sacco, Giovan Giuseppe Di Costanzo
PURPOSE: Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospective study, as second-line therapy after sorafenib failure, in patients with hepatocellular carcinoma (HCC). METHODS: 117 patients undergoing MC were compared to 112 patients, eligible for this treatment, but undergoing best supportive care (BSC) after sorafenib discontinuation for toxicity or HCC progression. The two groups were compared for demographic and clinical features...
December 16, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29234631/sorafenib-versus-hepatic-arterial-infusion-chemotherapy-as-initial-treatment-for-hepatocellular-carcinoma-with-advanced-portal-vein-tumor-thrombosis
#19
Michihisa Moriguchi, Takeshi Aramaki, Hideyuki Nishiofuku, Rui Sato, Koiku Asakura, Kanji Yamaguchi, Toshihiro Tanaka, Masahiro Endo, Yoshito Itoh
Objective: To investigate the validity of hepatic arterial infusion chemotherapy with low-dose 5-fluorouracil and cisplatin (LFP) versus sorafenib as first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (Vp3, Vp4). Patients and Methods: We retrospectively reviewed the cases of Child-Pugh A advanced HCC with Vp3 or Vp4 treated with LFP or sorafenib between October 2002 and December 2013. Results: There were 32 patients in the LFP group and 14 patients in the sorafenib group...
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29233562/comparison-of-radiation-therapy-modalities-for-hepatocellular-carcinoma-with-portal-vein-thrombosis-a-meta-analysis-and-systematic-review
#20
Chai Hong Rim, Chul Yong Kim, Dae Sik Yang, Won Sup Yoon
PURPOSE: We performed a meta-analysis and systematic review to compare the radiotherapy (RT) modalities for hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). MATERIALS AND METHODS: We searched the PubMed, EMBASE, Medline, and Cochrane library databases. The primary endpoint was the 1-year overall survival (OS), and response rate (RR), local control (LC), 2-year OS, and grade ≥3 toxicity incidence were evaluated as secondary endpoints. RESULTS: Thirty-seven studies comprising 2513 patients were included...
December 9, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
keyword
keyword
77310
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"